Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Tinea Pedis Treatment Market

Tinea Pedis Treatment Market Trends

Report ID: GMI9143
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Tinea Pedis Treatment Market Trends

Increasing prevalence of tinea pedis contributes significantly to the market growth.
Tinea pedis affects a significant portion of the population worldwide. For instance, according to an article published by National Institutes of Health in 2023, it is estimated that approximately 3% of world’s population have tinea pedis. The infection is particularly prevalent among individuals who frequently use communal areas such as gyms, locker rooms, and swimming pools, contributing to the market growth.
Additionally, the recurrent nature of the infection prompts ongoing demand for effective treatments and preventive measures, boosting market growth.
Furthermore, as awareness increases, there is a greater focus on preventive measures, such as proper foot hygiene and the use of antifungal powders, which can reduce the risk of developing the infection. This increased awareness of tinea pedis and its symptoms drives demand for treatments and preventive products.
Moreover, availability of a broad selection of OTC antifungal treatments, including creams, gels, sprays, powders, and lotions supports the growth of this market due to their easy accessibility and convenience.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Tinea pedis treatment market size was USD 1.3 billion in 2023 and is expected to register 4.3% CAGR from 2024-2032 owing to the rising prevalence of athlete's foot, driving demand for effective treatments worldwide.

Tinea pedis treatment industry from the antifungal segment recorded 75.7% share in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to their proven efficacy in treating athlete's foot.

North America tinea pedis treatment industry reached USD 860.8 million in 2023 and is expected to register a commendable CAGR from 2024-2032 due to high prevalence of tinea pedis, largely because of lifestyle factors such as active participation in sports and fitness activities in the region.

Bayer AG, Glenmark Pharmaceuticals Limited, Pfizer, Inc., Sebela Pharmaceuticals Holdings Inc., Smith & Nephew plc, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Limited, and Viatris Inc., are some of the major tinea pedis treatment companies worldwide.